AI Insight
This multicentre, double-blind, randomised controlled trial conducted in China evaluated tirofiban as an adjunctive therapy in acute ischaemic stroke patients who had successful endovascular reperfusion of anterior-circulation large-vessel occlusions. The study found that tirofiban increased the likelihood of functional independence compared to placebo. While symptomatic intracranial haemorrhage occurred numerically more frequently in the tirofiban group, the difference was not statistically significant, though this bleeding risk requires careful consideration in clinical decision-making.
Why it matters
This trial provides evidence for a potential adjunctive pharmacological treatment that could improve functional outcomes in stroke patients following successful mechanical thrombectomy. The findings may influence clinical protocols for post-reperfusion management, though the bleeding risk necessitates careful patient selection and risk-benefit assessment in practice.
Understand the Science
In patients with acute ischaemic stroke due to anterior-circulation large-vessel occlusion achieving successful reperfusion, adjunctive tirofiban increased the likelihood of functional independence compared with placebo. Although symptomatic intracranial haemorrhage occurred numerically more often with tirofiban, the between-group difference was not significant, and this finding warrants caution when weighing potential benefit against bleeding risk.